paritaprevir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Hepatitis Virus C (HVC) protease inhibitors 4913 1216941-48-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • paritaprevir dihydrate
  • paritaprevir
  • veruprevir
  • ABT-450
  • paritapravir
inhibits HCV NS3 protease
  • Molecular weight: 765.89
  • Formula: C40H43N7O7S
  • CLOGP: 6.28
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 3
  • TPSA: 189.65
  • ALOGS: -4.99
  • ROTB: 6

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 1.37 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.74 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.71 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2014 EMA
Dec. 19, 2014 FDA ABBVIE INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Jaundice 546.59 22.76 200 8527 30113 53310226
Blood bilirubin increased 406.96 22.76 169 8558 35561 53304778
Hyperbilirubinaemia 356.63 22.76 113 8614 10956 53329383
Hepatic failure 289.10 22.76 133 8594 35673 53304666
Ascites 211.12 22.76 111 8616 39624 53300715
Hepatocellular carcinoma 180.52 22.76 50 8677 3030 53337309
Hepatic encephalopathy 149.64 22.76 59 8668 10800 53329539
Hepatic cirrhosis 126.95 22.76 61 8666 17961 53322378
Anaemia 112.01 22.76 178 8549 276540 53063799
Asthenia 94.99 22.76 187 8540 343403 52996936
Vomiting 89.62 22.76 228 8499 496911 52843428
Nausea 84.18 22.76 292 8435 755799 52584540
Pruritus 74.03 22.76 154 8573 293678 53046661
Drug ineffective 72.71 22.76 22 8705 817223 52523116
Renal impairment 70.19 22.76 77 8650 83241 53257098
Haemoglobin decreased 67.69 22.76 97 8630 137210 53203129
Child-Pugh-Turcotte score increased 67.41 22.76 11 8716 43 53340296
Yellow skin 64.73 22.76 21 8706 2185 53338154
Bilirubin conjugated increased 60.18 22.76 21 8706 2730 53337609
Decreased appetite 57.99 22.76 116 8611 214858 53125481
Ocular icterus 56.67 22.76 22 8705 3857 53336482
Chromaturia 50.87 22.76 32 8695 15918 53324421
Hyperkalaemia 43.69 22.76 49 8678 54207 53286132
Hepatorenal syndrome 42.39 22.76 15 8712 2030 53338309
Varices oesophageal 40.19 22.76 16 8711 2996 53337343
Encephalopathy 39.95 22.76 39 8688 36769 53303570
Off label use 39.57 22.76 14 8713 472198 52868141
Upper gastrointestinal haemorrhage 38.85 22.76 28 8699 17402 53322937
Hepatic cancer 37.87 22.76 16 8711 3485 53336854
Oesophageal varices haemorrhage 37.05 22.76 12 8715 1241 53339098
Pain 36.51 22.76 26 8701 588372 52751967
Portal vein thrombosis 35.25 22.76 14 8713 2605 53337734
Fatigue 34.98 22.76 221 8506 730285 52610054
Blood bilirubin unconjugated increased 34.78 22.76 9 8718 419 53339920
Hepatitis C 34.00 22.76 18 8709 6483 53333856
Insomnia 32.61 22.76 85 8642 186987 53153352
Renal failure 31.96 22.76 64 8663 118388 53221951
Hyponatraemia 29.68 22.76 59 8668 108548 53231791
Drug interaction 28.82 22.76 90 8637 219239 53121100
Acute hepatic failure 28.73 22.76 23 8704 16697 53323642
Drug hypersensitivity 27.67 22.76 5 8722 265237 53075102
Alanine aminotransferase increased 26.39 22.76 52 8675 95043 53245296
Aspartate aminotransferase increased 24.59 22.76 47 8680 83982 53256357
Oedema due to hepatic disease 24.24 22.76 4 8723 17 53340322
Hypertransaminasaemia 23.53 22.76 12 8715 4004 53336335

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood bilirubin increased 393.86 20.74 205 9692 38579 32465050
Jaundice 286.17 20.74 159 9738 33999 32469630
Hepatocellular carcinoma 236.32 20.74 96 9801 10174 32493455
Ascites 229.13 20.74 146 9751 40045 32463584
Hepatic failure 219.40 20.74 136 9761 35544 32468085
Hepatic cirrhosis 179.32 20.74 92 9805 16717 32486912
Hyperbilirubinaemia 166.20 20.74 89 9808 17641 32485988
Renal impairment 146.03 20.74 159 9738 91813 32411816
Hepatic encephalopathy 145.88 20.74 77 9820 14818 32488811
Fatigue 90.55 20.74 272 9625 350429 32153200
Yellow skin 70.10 20.74 26 9871 2151 32501478
Ocular icterus 67.63 20.74 28 9869 3104 32500525
Hepatitis C 64.46 20.74 44 9853 13474 32490155
Anaemia 62.76 20.74 179 9718 223445 32280184
Drug interaction 58.66 20.74 172 9725 218013 32285616
Hepatitis C RNA increased 57.19 20.74 15 9882 389 32503240
Encephalopathy 53.80 20.74 59 9838 34198 32469431
Blood bilirubin unconjugated increased 53.01 20.74 16 9881 698 32502931
Haemoglobin decreased 52.79 20.74 114 9783 119557 32384072
Oesophageal varices haemorrhage 50.86 20.74 23 9874 3156 32500473
Asthenia 49.66 20.74 171 9726 235773 32267856
Insomnia 42.41 20.74 94 9803 100254 32403375
Distributive shock 41.13 20.74 14 9883 901 32502728
Portal hypertension 39.72 20.74 21 9876 4043 32499586
Gastric varices haemorrhage 37.46 20.74 10 9887 278 32503351
Alanine aminotransferase increased 37.15 20.74 77 9820 78402 32425227
Bilirubin conjugated increased 37.04 20.74 19 9878 3439 32500190
Vomiting 34.24 20.74 152 9745 235405 32268224
Child-Pugh-Turcotte score increased 32.74 20.74 7 9890 72 32503557
Chromaturia 31.98 20.74 30 9867 14448 32489181
Hepatitis B reactivation 31.40 20.74 17 9880 3432 32500197
Varices oesophageal 27.75 20.74 16 9881 3645 32499984
Nausea 27.45 20.74 179 9718 320670 32182959
Palpitations 26.82 20.74 43 9854 35926 32467703
Hepatorenal syndrome 26.80 20.74 14 9883 2631 32500998
Death 26.14 20.74 48 9849 382469 32121160
Immunosuppressant drug level increased 25.12 20.74 17 9880 5128 32498501
Alpha 1 foetoprotein increased 24.49 20.74 9 9888 725 32502904
Neutropenia 23.59 20.74 7 9890 142168 32361461
Acute on chronic liver failure 23.48 20.74 6 9891 140 32503489
Drug ineffective 22.09 20.74 53 9844 383424 32120205
Hepatic cancer 22.02 20.74 18 9879 7222 32496407
Irritability 21.94 20.74 32 9865 24622 32479007
Arteriovenous malformation 21.19 20.74 8 9889 695 32502934
Hepatic lesion 21.13 20.74 13 9884 3334 32500295

Pharmacologic Action:

SourceCodeDescription
ATC J05AP52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP53 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000182638 HCV NS3/4A Protease Inhibitors
FDA EPC N0000182639 Hepatitis C Virus NS3/4A Protease Inhibitor
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190107 Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA N0000190108 Organic Anion Transporting Polypeptide 1B3 Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:36044 anti-virus drug
CHEBI has role CHEBI:64924 hepatitis C protease inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.23 acidic
pKa2 13.41 acidic
pKa3 3.65 Basic
pKa4 3.01 Basic
pKa5 0.2 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
12.5MG;75MG;50MG TECHNIVIE ABBVIE INC N207931 July 24, 2015 DISCN TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
12.5MG;75MG;50MG TECHNIVIE ABBVIE INC N207931 July 24, 2015 DISCN TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
12.5MG;75MG;50MG TECHNIVIE ABBVIE INC N207931 July 24, 2015 DISCN TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10201584 May 17, 2032 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 10201542 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 250MG BASE;12.5MG, 75MG, 50MG VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 DISCN TABLET ORAL 9629841 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10105365 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9333204 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
EQ 200MG BASE;8.33MG;50MG;33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9744170 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D10580 KEGG_DRUG
1456607-71-8 SECONDARY_CAS_RN
4034027 VANDF
CHEBI:85188 CHEBI
CHEMBL3391662 ChEMBL_ID
C585405 MESH_SUPPLEMENTAL_RECORD_UI
11273 IUPHAR_LIGAND_ID
9739 INN_ID
DB09297 DRUGBANK_ID
OU2YM37K86 UNII
45110509 PUBCHEM_CID
1597373 RXNORM
30777 MMSL
d08321 MMSL
015826 NDDF
714420001 SNOMEDCT_US
714428008 SNOMEDCT_US
C3864824 UMLSCUI

Pharmaceutical products:

None